Adolescent Male Human Papillomavirus Vaccination

about

Expanded strain coverage for a highly successful public health tool: prophylactic 9-valent human papillomavirus vaccine.HPV vaccination in boys: Determining the clinical relevance of this strategy.

P2860

Q38682763-880BC99E-9744-4758-A281-378CF1053CF2 Q42376432-DE784C43-06F8-4B5E-88A3-DBDE2D49127A

P2860

Adolescent Male Human Papillomavirus Vaccination

Item

http://www.wikidata.org/entity/Q36997691

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Adolescent Male Human Papillomavirus Vaccination

@en

type

Item

label

Adolescent Male Human Papillomavirus Vaccination

@en

prefLabel

Adolescent Male Human Papillomavirus Vaccination

@en

P1476

Adolescent Male Human Papillomavirus Vaccination

@en

P2093

Adrienne Stolfi

http://www.w3.org/2001/XMLSchema#string

Gregory M Eberhart

http://www.w3.org/2001/XMLSchema#string

Maria T Nanagas

http://www.w3.org/2001/XMLSchema#string

Sherman J Alter

http://www.w3.org/2001/XMLSchema#string

Vivian C Nanagas

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Children who have received no vaccines: who are they and where do they live?

Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.

Acceptability of prophylactic human papillomavirus vaccination among adult men.

Attitudes toward HPV vaccination among low-income and minority parents of sons: a qualitative analysis.

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.

HPV vaccine and males: issues and challenges.

P304

2333794X16642373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2333794X16642373

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27336012

http://www.w3.org/2001/XMLSchema#string

P921

teenager

P932

4905155

http://www.w3.org/2001/XMLSchema#string

Adolescent Male Human Papillomavirus Vaccination

about

P2860

P2860

Adolescent Male Human Papillomavirus Vaccination

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932